Letter by Li et al Regarding Article, “ SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension”

HomeCirculationVol. 148, No. 22Letter by Li et al Regarding Article, “SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension” No AccessLetterRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessLetterRequest AccessFull TextLetter by Li et al Regarding Article, “SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension” Guling Li, Hui Chen and Chuanli Ren Guling LiGuling Li Department of Laboratory Medicine (G.L., C.R.), Clinical Medical College of Yangzhou University, China. *G. Li and H. Chen contributed equally. Search for more papers by this author , Hui ChenHui Chen Department of Gerontology (H.C.), Clinical Medical College of Yangzhou University, China. *G. Li and H. Chen contributed equally. Search for more papers by this author and Chuanli RenChuanli Ren https://orcid.org/0000-0002-8386-3586 Department of Laboratory Medicine (G.L., C.R.), Clinical Medical College of Yangzhou University, China. Search for more papers by this author Originally published27 Nov 2023https://doi.org/10.1161/CIRCULATIONAHA.123.066230Circulation. 2023;148:1823–1824"Letter by Li et al Regarding Article, “SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension”." Circulation, 148(22), pp. 1823–1824Footnotes*G. Li and H. Chen contributed equally.Circulation is available at www.ahajournals.org/journal/circREFERENCES1. Walters R, Vasilaki E, Aman J, Chen CN, Wu Y, Liang OD, Ashek A, Dubois O, Zhao L, Sabrin F, et al. SOX17 enhancer variants disrupt transcription factor binding and enhancer inactivity drives pulmonary hypertension.Circulation. 2023; 147:1606–1621. doi: 10.1161/circulationaha.122.061940LinkGoogle Scholar2. Gräf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, Hodgson J, Liu B, Salmon RM, Southwood M, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension.Nat Commun. 2018; 9:1416. doi: 10.1038/s41467-018-03672-4CrossrefMedlineGoogle Scholar3. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).Eur Heart J. 2016; 37:67–119. doi: 10.1093/eurheartj/ehv317CrossrefMedlineGoogle Scholar4. Southgate L, Machado RD, Gräf S, Morrell NW. Molecular genetic framework underlying pulmonary arterial hypertension.Nat Rev Cardiol. 2020; 17:85–95. doi: 10.1038/s41569-019-0242-xCrossrefMedlineGoogle Scholar5. Golpon HA, Geraci MW, Moore MD, Miller HL, Miller GJ, Tuder RM, Voelkel NF. HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema.Am J Pathol. 2001; 158:955–966. doi: 10.1016/S0002-9440(10)64042-4CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetails November 28, 2023Vol 148, Issue 22 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.066230PMID: 38011241 Originally publishedNovember 27, 2023 PDF download Advertisement